Neurogene (NGNE) Common Equity (2013 - 2026)
Neurogene's (NGNE) quarterly Common Equity came in at $237.8 million in Q1 2026, down 18.51% YoY from $291.8 million in Q1 2025, and down 10.23% on a QoQ basis from $264.9 million in Q4 2025.
Neurogene (NGNE) Common Equity (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 14 years of Common Equity data on file, last reported at $237.8 million in Q1 2026.
- Quarterly Common Equity fell 18.51% year-over-year to $237.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $237.8 million (down 18.51% YoY) and the FY2025 annual result came in at $264.9 million, down 14.66% from the prior year.
- Common Equity retreated to $237.8 million in Q1 2026, from $264.9 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $310.4 million in Q4 2024 to a low of -$183.2 million in Q3 2023.
- A 5-year average of $117.0 million and a median of $155.0 million in 2024 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 227.64% in 2023, down 273.42% in 2023.
- Tracing NGNE's Common Equity over 5 years: stood at -$145.7 million in 2022, then soared by 227.64% to $186.0 million in 2023, then surged by 66.85% to $310.4 million in 2024, then dropped by 14.66% to $264.9 million in 2025, then fell by 10.23% to $237.8 million in 2026.
- The last three Common Equity figures came in at $237.8 million (Q1 2026), $264.9 million (Q4 2025), and $265.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | 217.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 217.13 Mn |
| Mar 31, 2026 | 237.78 Mn |
| Dec 31, 2025 | 264.89 Mn |
| Sep 30, 2025 | 265.54 Mn |
| Jun 30, 2025 | 273.26 Mn |
| Mar 31, 2025 | 291.80 Mn |
| Dec 31, 2024 | 310.38 Mn |
| Sep 30, 2024 | 137.41 Mn |
| Jun 30, 2024 | 155.01 Mn |
| Mar 31, 2024 | 170.78 Mn |
| Dec 31, 2023 | 186.02 Mn |
| Sep 30, 2023 | -183.21 Mn |
| Jun 30, 2023 | -169.05 Mn |
| Mar 31, 2023 | -157.60 Mn |
| Dec 31, 2022 | -145.74 Mn |
| Sep 30, 2022 | 105.65 Mn |
| Jun 30, 2022 | 116.71 Mn |
| Mar 31, 2022 | 130.09 Mn |
| Dec 31, 2021 | 142.86 Mn |
| Sep 30, 2021 | 154.87 Mn |